PharmD | Pharmacist | Medical Writer (Pharmacology & Treatment Content)
At a Glance
Gerardo Sison, PharmD, is a licensed pharmacist specializing in medication and treatment-related content. His work focuses on translating pharmacologic information into clear, evidence-based content for patient and consumer audiences.
Professional Summary
Gerardo Sison, PharmD, is a pharmacist and medical writer who specializes in creating clear, accurate health content focused on medications and treatment. His work centers on translating complex pharmacologic and clinical information into language that is accessible to patient and consumer audiences.
He has worked with healthcare organizations, clinics, and medical professionals to develop long-form content, educational materials, and treatment-focused resources. His background in evaluating medical literature supports a structured, evidence-informed approach to health communication.
Role at PolicyLab
Gerardo serves as a medical writer and contributor for PolicyLab, with a focus on medication-related topics, treatment explanations, and pharmacologic education. He develops content that translates complex drug information into clear, accessible language for patient and consumer audiences.
His work includes explaining how medications are used, how they work, and how they fit into broader treatment plans, with an emphasis on clarity, accuracy, and responsible communication of health information.
Areas of Expertise
Professional Experience
Gerardo is a pharmacist with experience spanning both clinical and content-focused roles. In addition to his pharmacy background, he has worked as a health editor, content producer, and medical writer for clinics, associations, and healthcare-focused organizations.
His work includes developing long-form medical content designed to perform in search while maintaining accuracy and compliance, as well as collaborating with healthcare professionals to ensure content quality and relevance.
Editorial Approach
Gerardo approaches medical content with a focus on clarity, structure, and responsible communication of pharmacologic information. His work emphasizes translating complex topics into accessible explanations without oversimplifying key details.
He prioritizes accuracy and readability, particularly in areas where patients and consumers are making decisions based on the information presented.
Articles by Gerardo Sison
Gerardo contributes content related to medications, treatment options, and health education, helping ensure that PolicyLab articles are clear, accurate, and useful for readers.
Professional Profile
Website: https://lettermed.com
LinkedIn
Disclaimer
Content written by Gerardo Sison, PharmD, is for informational purposes only and does not replace professional medical advice, diagnosis, or treatment.
Editorial Disclosure: Our clinical reviews are independent and science-led. To support our research and testing, we may earn a commission if you sign up or purchase through certain links on this page at no additional cost to you. This does not influence our rankings or medical evaluations. If you’ve decided on trying compounded semaglutide, whether … Read more
Wegovy (Semaglutide): Weight-Loss Uses, Dosing, Clinical Trial Results, Risks, and Cost Wegovy: Key Facts Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult your healthcare professional before starting any new medication. Wegovy Overview Wegovy is a GLP-1 (glucagon-like peptide-1) agonist prescribed to manage weight in those who are … Read more
Ozempic (Semaglutide): Uses, Dosing, Clinical Trial Results, Risks, and Cost Ozempic: Key Facts Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult your healthcare professional before starting any new medication. Ozempic Overview Ozempic (semaglutide) is a prescription medication in the GLP-1 receptor agonist drug class. First approved by … Read more
Semaglutide is one of the leading weight-loss medications in the United States, with studies showing an average weight loss of around 15% or more. Best known for its effects on managing blood sugar levels and promoting weight loss, it’s often recognized by the brand names Ozempic, Wegovy, and Rybelsus. Despite the potential benefits of taking … Read more
TL;DR Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult your healthcare professional before starting any new medication. Those who live with type 2 diabetes or obesity often need support in the form of medication. Glucagon-like peptide-1 (GLP-1) agonists are prescribed as a safe and effective option based … Read more
TL;DR Managing weight isn’t just a cosmetic concern. It’s often a key part of controlling blood pressure or cholesterol levels and improving other health outcomes. However, diet and lifestyle changes aren’t always enough. Medications that mimic the GLP-1 hormone can be effective for weight loss and related conditions such as diabetes. Zepbound is a newer … Read more
TL;DR Treatment options have expanded over the years when it comes to type 2 diabetes. GLP-1 medications are some of the newest drugs, approved for managing blood sugar levels and weight loss. Medications like Monunjaro go one step further in targeting both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1), two key hormones involved in … Read more
With clinical trial results showing an average weight loss of over 20% for many people, there’s no question that tirzepatide is an effective drug. Under the brand names Mounjaro® (for type 2 diabetes) and Zepbound® (for obesity and sleep apnea), it’s now one of the most in-demand GLP-1/GIP medications on the market. However, it’s also one of … Read more
GLP-1 (glucagon-like peptide-1) drugs are continuing to become household names for weight loss. They activate a receptor that has potential effects extending beyond just managing weight, with benefits on blood sugar levels, as well as heart, kidney, and liver health. One of the newest approved options is tirzepatide. However, unlike GLP-1 drugs like semaglutide and … Read more
